Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice.
about
Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?Transcriptome meta-analysis reveals a dysregulation in extra cellular matrix and cell junction associated gene signatures during Dengue virus infectiont(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression.IFATS collection: Combinatorial peptides identify alpha5beta1 integrin as a receptor for the matricellular protein SPARC on adipose stromal cells.A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.MicroRNA-584 and the protein phosphatase and actin regulator 1 (PHACTR1), a new signaling route through which transforming growth factor-β Mediates the migration and actin dynamics of breast cancer cellsDistinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndromeClinical utility of lenalidomide in the treatment of myelodysplastic syndromesChromosome 5q deletion is extremely rare in patients with myelofibrosisImportant genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.Original Research: A case-control genome-wide association study identifies genetic modifiers of fetal hemoglobin in sickle cell disease.A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.Molecular mechanisms involved in the progression of myelodysplastic syndrome.Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.Biology and treatment of the 5q- syndrome.Molecular dissection of the 5q deletion in myelodysplastic syndrome.Diagnostic challenges in the myelodysplastic syndromes: the current and future role of genetic and immunophenotypic studies.Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesTherapy-related myeloid neoplasms: when genetics and environment collide.Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletionCXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance.SPARC deficiency affects bone marrow stromal function, resulting in impaired B lymphopoiesis.The 5q- syndrome: biology and treatment.Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.
P2860
Q26828777-A16A96B1-2C95-45A5-9E27-BE2678365523Q27468674-53FEA283-A69E-47B4-841C-A3E6573F1E08Q33338784-5DEDC63A-B31F-454E-8B37-4AA127228419Q33347082-73646063-CFAB-4CD0-B46F-B20BAB964907Q33579912-0D818EE4-7AB7-4FD4-8433-E971D82BD9EFQ34332277-BC40B95E-7D0A-4779-B3E0-2A602D08D9C2Q34705185-E5AA7BBE-8EE9-44CE-9171-E79FB838AC96Q34783754-569E9CE9-E691-47C1-A933-3ABEC0CBFC29Q35535523-28A3388B-7703-4365-9E34-365AFD60597AQ36417421-94B20870-06EC-4410-BF31-C5A41A806759Q37006888-EB641DF8-D18A-47E3-9CF4-645545733FD5Q37107201-5DABAE85-7CF6-4CDE-838E-0051712DA878Q37293324-1AA4ACFD-734C-40FE-A2DA-55FBBF9E3201Q37423777-C54C5811-01C2-46A2-9C9D-375F5F2A072FQ37679943-629B163B-E05A-4153-BBD7-7F2D08D1A2A1Q37707390-C999AB04-901C-49FE-983E-A2FA57AF99F6Q37799831-F262F836-B527-41C2-91D2-22CFE936DDEDQ37842349-26AF6D96-AC5A-4E9D-9BD9-387A9CFC55DEQ37937810-4897EF55-AE3B-489F-AE4B-92EEB349EB5DQ38089064-EC70D39D-2C3F-4EF5-95C5-AD36B144D6ABQ38135713-FBBFF630-7034-407C-BFD9-846AE96E72F3Q38611096-69E7BC94-4B28-4566-893D-C11D1DEF8F5AQ42253318-0935C388-217A-4AEC-AB33-C6CF3BC8764EQ43226905-5D0EE1B5-DAC8-406D-BCA1-7D3918417027Q53605588-CE39CA52-68AD-4054-B1FA-25DAC9BCA405Q54539679-6A2E1666-CBB9-498C-9F3E-8B93940E9619Q54594035-F73D902F-1C71-4604-9129-EC720BC89AD2
P2860
Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Common deleted genes in the 5q ...... formation in SPARC null mice.
@ast
Common deleted genes in the 5q ...... formation in SPARC null mice.
@en
type
label
Common deleted genes in the 5q ...... formation in SPARC null mice.
@ast
Common deleted genes in the 5q ...... formation in SPARC null mice.
@en
prefLabel
Common deleted genes in the 5q ...... formation in SPARC null mice.
@ast
Common deleted genes in the 5q ...... formation in SPARC null mice.
@en
P2093
P2860
P356
P1433
P1476
Common deleted genes in the 5q ...... formation in SPARC null mice.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404852
P577
2007-07-12T00:00:00Z
P5875
P6179
1046554344